Literature DB >> 16676101

[Brain natriuretic peptide in primary pulmonary hypertension].

Douglas Greig1, Pablo Castro, Marcela Ferrada, Jongsung Lim, Cristián López, Sandra Braun, Samuel Córdova, Margarita Salazar.   

Abstract

BACKGROUND: Primary pulmonary hypertension (PPH) is a progressive disease leading to right heart failure and death. Right heart catherization and maximal or submaximal tests are employed to assess the course of the disease. A neurohormonal parameter such as pro-brain natriuretic peptide (BNP) would be helpful in the assessment of these patients. AIM: To study the correlation of BNP with functional status and non-invasive hemodynamic determinations in patients with PPH.
MATERIAL AND METHODS: Twelve patients (mean age: 48 years; 58% female) were evaluated with 6 minutes walk distance test (6-min WT), plasma BNP, systolic pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR) and cardiac output (CO) determined by echocardiogram. Plasma BNP levels were compared with normal subjects.
RESULTS: BNP levels were increased in PPH patients (1270+/-547 vs 48+/-8 pg/ml, p-value <0.01). Mean PAPs was 82+/-27 mmHg and the mean distance walked in 6 minutes was 407+/-113 meters. BNP levels were positively correlated with PVR (r=0.58, p-value=0.006) and negatively correlated with 6-min WT (r=-0.83, p-value <0.001). No correlation was found between BNP levels, PAPs and CO.
CONCLUSIONS: In PPH patients, BNP levels are increased and correlate with functional class and PVR. Follow-up studies are needed to evaluate the role of BNP as a marker of progression and therapeutic response in PPH patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16676101     DOI: 10.4067/s0034-98872006000300005

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

1.  N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH.

Authors:  Sara Simeoni; Giuseppe Lippi; Antonio Puccetti; Martina Montagnana; Elisa Tinazzi; Daniele Prati; Roberto Corrocher; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2007-12-19       Impact factor: 2.631

Review 2.  Natriuretic peptides in cardiovascular diseases.

Authors:  Mariusz Piechota; Maciej Banach; Anna Jacoń; Jacek Rysz
Journal:  Cell Mol Biol Lett       Date:  2008-04-10       Impact factor: 5.787

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.